Back to today’s briefing

Story perspectives

Analysts Suggest 5 Stocks Amid Myriad Genetics Hold Rating

1/31/2025

27 4

Summary

Analysts Recommend Alternatives

Myriad Genetics (NASDAQ:MYGN) currently has a "Hold" rating, but top analysts recommend exploring five more promising stocks. With shares trading at $12.54, they remain below Piper Sandler's lowered price target of $14. Notably, institutional investors dominate the company, holding 99.02% of its shares.

Summary

Natera's Stock Surge

Natera, Inc. is making waves in the investment world, with a staggering 99.90% of its shares held by hedge funds. Analysts are optimistic, with TD Cowen boosting their price target from $155 to $175, as the stock currently sits at $181.20. The company also celebrated a remarkable 63.9% revenue surge, totaling $439.80 million last quarter.

History

Historical Context

Institutional investors have significantly influenced stock markets since the 1980s, reshaping corporate governance. The rise of hedge funds and private equity parallels past trends, like the 2008 financial crisis, which highlighted their market impact and regulatory challenges. Today, their dominance in companies like Myriad Genetics and Natera reflects this ongoing trend.

1 of 3

Analysts Recommend Alternatives

Myriad Genetics (NASDAQ:MYGN) currently has a "Hold" rating, but top analysts recommend exploring five more promising stocks. With shares trading at $12.54, they remain below Piper Sandler's lowered price target of $14. Notably, institutional investors dominate the company, holding 99.02% of its shares.

1 / 3